RxDoctor Payments Data

Carey Bartnicki, APRN

Family · Newcastle, OKNPI 1467868349

Payments from drug & device makers

$1,523in general payments, 2019–2025

Across 60 payments — averaging $25.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$892
  • E.r. Squibb & Sons, L.L.C.$164
  • Novo Nordisk$122
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
  • Amgen$81
  • Merck$56
  • plus $107 from 5 others

What the payments were for

  • Travel & lodging$60139%
  • Food & beverage$92261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,523 in reported general payments places this provider in the 75th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$27,033
Medicare patients
296
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$53,019
OzempicSemaglutide26$33,781
XareltoRivaroxaban31$27,939
FarxigaDapagliflozin Propanediol24$19,513
EntrestoSacubitril/Valsartan13$9,041
Clonidine14$3,380
Valsartan81$3,198
Dabigatran EtexilateDabigatran Etexilate Mesylate15$2,775
Ranolazine ErRanolazine26$2,589
Rosuvastatin Calcium206$2,492
Prasugrel Hcl17$2,336
Potassium Chloride94$1,705
Olmesartan Medoxomil48$1,673
Bisoprolol Fumarate67$1,285
Nitroglycerin PatchNitroglycerin27$977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$53,01977 claims
Novo NordiskOzempic$122$33,78126 claims
NovartisEntresto$19$9,04113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,026 family providers in Oklahoma.

Other family in Newcastle

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →